The Institute for Clinical and Economic Review
Patients, in consultation with their doctors, should make their own medical decisions. But with increasing frequency, an outside organization known as the Institute for Clinical and Economic Review is influencing what treatment options are available for consideration. Today, patients’ access to innovative drugs, life-saving devices and diagnostic testing often rides on this third-party’s value assessment. […]
Fast Facts: Biosimilars Policy in 2018 & Beyond
Since Congress created an approval pathway for follow-on biological drugs in 2009, nearly a dozen biosimilars have been approved by the FDA. Many more are in the pipeline.
Fast Facts: Pharmacovigilance
As many as one out of three drugs on the U.S. market may have safety issues, according to a recent study published in the Journal of the American Medical Association.1 The statistic highlights a key challenge of modern medicine: the need to track adverse events long after regulatory agencies have approved new drugs. Read the […]
Fast Facts: Co-Pay Coupons
People are living longer, healthier lives today with the help of advanced medicine. But innovative drugs can be expensive. Insurance companies increasingly shift these drug costs to patients through coinsurance and co-pay requirements. In recent years, drug manufacturers have responded by offering co-pay coupons and co-pay assistance programs to help patients manage higher out-of-pocket expenses […]
